Novel glioblastoma therapeutics
|Funding from Vinnova||SEK 2 000 000|
|Project duration||December 2017 - December 2018|
|Venture||Innovationsprojekt i företag 2017|
Purpose and goal
The Beactica allosteric LSD1 modulator programme have advanced through lead generation to in vivo proof of principle in an advanced glioblastoma model, with an improved understanding of the mechanism of action.
Expected results and effects
The promising results from the advanced glioblastoma proof-of-principle model, and indication of efficacy in backup cancer indications, open the door for preclinical development and expansion into other indications.
Planned approach and implementation
Activities in the project have been distributed between chemistry and in vitro assays at Beactica, while key in vitro disease models have been performed as part of academic collaborations, and highly specialized contract research organizations have performed critical in vivo models. The semi-virtual organization proved to be highly flexible and able to handle complex studies with the required wide range of scientific and disciplines.